Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apx-3330. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 known ✓ | P27695 | 12/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apx-3330 SCHEMBL3758719 | 1.00 | APEX1 (1.00) | APEX1TDP1MAPTALDH1A1THRB | |
| SCHEMBL3755865 | 0.94 | APEX1 (1.00) | APEX1TDP1MAPTALDH1A1THRB | |
| SCHEMBL3755868 | 0.94 | APEX1 (1.00) | APEX1TDP1MAPTALDH1A1THRB | |
| SCHEMBL3760705 | 0.89 | APEX1 (0.84) | APEX1TDP1MAPTALDH1A1THRB | |
| SCHEMBL3760706 | 0.89 | APEX1 (0.84) | APEX1TDP1MAPTALDH1A1THRB | |
| SCHEMBL17689291 | 0.86 | APEX1 (0.75) | APEX1TDP1ALDH1A1PDE3APPARG | |
| SCHEMBL15711340 | 0.86 | APEX1 (1.00) | APEX1TDP1MAPTALDH1A1THRB | |
| SCHEMBL17277628 | 0.86 | APEX1 (1.00) | APEX1TDP1MAPTALDH1A1THRB | |
| SCHEMBL17277627 | 0.84 | APEX1 (0.72) | APEX1TDP1MAPTALDH1A1THRB | |
| SCHEMBL17689687 | 0.84 | APEX1 (0.72) | APEX1TDP1MAPTALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312308-B2 | Salts and esters of APX3330 and therapeutic uses thereof | OPUS GENETICS, INC. (US) | 2025-05-27 | — | — | US | claimed |
| WO-2025106621-A1 | TREATMENT OF ULCERATIVE COLITIS AND SYMPTOMS THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2025-05-22 | — | — | WO | claimed |
| US-20250099467-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | RGCM SA LLC, AS PURCHASER AGENT | 2025-03-27 | — | — | US | claimed |
| EP-4469086-A2 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | Verastem, Inc. (US) | 2024-12-04 | — | — | EP | claimed |
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | claimed |
| WO-2023147297-A2 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2023-08-03 | — | — | WO | claimed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | claimed |
| CN-108524511-B | Cancer therapy | 阿斯兰制药有限公司 | 2023-02-28 | — | — | CN | claimed |
| US-11382903-B2 | Cancer therapy | ASLAN PHARMACEUTICALS PTE. LTD. (SG) | 2022-07-12 | — | — | US | claimed |
| US-11351130-B2 | Prevention and reversal of inflammation induced DNA damage | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-06-07 | — | — | US | claimed |
| US-11331294-B2 | Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-05-17 | — | — | US | claimed |
| US-20220062205-A1 | TREATMENT OF GASTROINTESTINAL DISORDERS AND SYMPTOMS THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2022-03-03 | — | — | US | claimed |
| US-20190151326-A1 | CANCER THERAPY | ASLAN PHARMACEUTICALS PTE. LTD. (SG) | 2019-05-23 | — | — | US | claimed |
| US-20190038610-A1 | CANCER THERAPY | ASLAN PHARMACEUTICALS PTE. LTD. (SG) | 2019-02-07 | — | — | US | claimed |
| US-20260108483-A1 | METHODS AND COMPOSITIONS FOR PREVENTING THE PROGRESSION OF DIABETIC RETINOPATHY AND RELATED CONDITIONS | OPUS GENETICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250387503-A1 | DRUG CONJUGATES FOR THE TREATMENT OF OCULAR DISORDERS | ASCENDIS PHARMA OPHTHALMOLOGY DIV A/S (DK) | 2025-12-25 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20100297113-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2010-11-25 | — | — | US | disclosed |
| WO-2009042544-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20070099926-A1 | Combination therapy for treating chronic inflammatory diseases | MERCK SHARP & DOHME CORP. | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382903-B2 | Cancer therapy | DHODH, MCL1, DOHH | APEX1 1269/4885TDP1 1589/4885MAPT 4090/4885 |
| US-20250387503-A1 | DRUG CONJUGATES FOR THE TREATMENT OF OCULAR DISORDERS | VEGFA, CD44, KDR | APEX1 3880/4885TDP1 3870/4885MAPT 1475/4885 |
| US-11331294-B2 | Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer | APEX1, NFE2, FEN1 | APEX1 1/4885TDP1 252/4885MAPT 4335/4885 |
| US-20250099467-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | BRAF, CHEK1, CHEK2 | APEX1 766/4885TDP1 235/4885MAPT 3516/4885 |
| US-11351130-B2 | Prevention and reversal of inflammation induced DNA damage | APEX1, FEN1, LIG1 | APEX1 1/4885TDP1 44/4885MAPT 4060/4885 |
| US-20190038610-A1 | CANCER THERAPY | DHODH, MCL1, DOHH | APEX1 1269/4885TDP1 1589/4885MAPT 4090/4885 |
| US-20100297113-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | APEX1, NQO1, REV1 | APEX1 1/4885TDP1 118/4885MAPT 2625/4885 |
| US-12312308-B2 | Salts and esters of APX3330 and therapeutic uses thereof | SLC10A1, AP3B1, SLC20A1 | APEX1 1642/4885TDP1 2875/4885MAPT 3273/4885 |
| US-20190151326-A1 | CANCER THERAPY | DHODH, MCL1, DOHH | APEX1 1269/4885TDP1 1589/4885MAPT 4090/4885 |
| US-20260108483-A1 | METHODS AND COMPOSITIONS FOR PREVENTING THE PROGRESSION OF DIABETIC RETINOPATHY AND RELATED CONDITIONS | SLC5A2, ALDH1A2, AQP3 | APEX1 4002/4885TDP1 3492/4885MAPT 3250/4885 |
| US-20220062205-A1 | TREATMENT OF GASTROINTESTINAL DISORDERS AND SYMPTOMS THEREOF | AP1G1, AP3B1, AP1M1 | APEX1 4/4885TDP1 340/4885MAPT 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.